S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
NASDAQ:KRYS

Krystal Biotech (KRYS) Price Target & Analyst Ratings

$96.06
+8.61 (+9.85%)
(As of 05/19/2023 08:48 PM ET)
Compare
Today's Range
$87.17
$97.31
50-Day Range
$72.39
$96.06
52-Week Range
$49.17
$97.31
Volume
1.34 million shs
Average Volume
213,811 shs
Market Capitalization
$2.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$115.80

Krystal Biotech Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$116.17
20.93% Upside
High Prediction$133.00
Average Prediction$116.17
Low Prediction$101.00
TypeCurrent
5/22/22 to 5/22/23
1 Month Ago
4/22/22 to 4/22/23
3 Months Ago
2/21/22 to 2/21/23
1 Year Ago
5/22/21 to 5/22/22
Consensus Rating
Buy
Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$116.17$115.80$106.75$101.60
Predicted Upside20.93% Upside41.15% Upside42.15% Upside57.01% Upside
Get Krystal Biotech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.


KRYS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KRYS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Krystal Biotech Stock vs. The Competition

TypeKrystal BiotechMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside20.93% Upside4,095.51% Upside173.87% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$105.00 ➝ $118.00+22.84%
4/17/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$102.00+15.80%
3/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$101.00+15.15%
2/28/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$133.00+70.21%
2/28/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$119.00+52.29%
2/28/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$79.00 ➝ $124.00+58.69%
(Data available from 5/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












KRYS Price Target - Frequently Asked Questions

What is Krystal Biotech's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Krystal Biotech stock is Buy based on the current 6 buy ratings for KRYS. The average twelve-month price prediction for Krystal Biotech is $116.17 with a high price target of $133.00 and a low price target of $101.00. Learn more on KRYS's analyst rating history.

Do Wall Street analysts like Krystal Biotech more than its competitors?

Analysts like Krystal Biotech more than other Medical companies. The consensus rating score for Krystal Biotech is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how KRYS compares to other companies.

Is Krystal Biotech being upgraded by Wall Street analysts?

Over the previous 90 days, Krystal Biotech's stock had 1 upgrade by analysts.

Does Krystal Biotech's stock price have much upside?

According to analysts, Krystal Biotech's stock has a predicted upside of 39.43% based on their 12-month price targets.

What analysts cover Krystal Biotech?

Krystal Biotech has been rated by Bank of America, Chardan Capital, Guggenheim, HC Wainwright, Stifel Nicolaus, The Goldman Sachs Group, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KRYS) was last updated on 5/22/2023 by MarketBeat.com Staff

My Account -